Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:Foster Jonathan P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:28,986Price:$0.69
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:George Robert E.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:14,493Price:$0.69
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:188,404Price:$0.69
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-13,204Price:--
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,216Price:$0.59
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:13,204Price:--
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,717Price:--
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,584Price:$0.58
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,717Price:--
-
Jun 22, 2023 (filed on Jun 26, 2023)Insider Name:Foster Jonathan P.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:259,688Price:--
Filings by filing date
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:Foster Jonathan P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:28,986Price:$0.69
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:George Robert E.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:14,493Price:$0.69
-
Dec 26, 2023 (filed on Dec 27, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:188,404Price:$0.69
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-13,204Price:--
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,216Price:$0.59
-
Jul 11, 2023 (filed on Jul 13, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:13,204Price:--
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,717Price:--
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,584Price:$0.58
-
Jul 02, 2023 (filed on Jul 05, 2023)Insider Name:Klemp Walter VOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,717Price:--
-
Jun 22, 2023 (filed on Jun 26, 2023)Insider Name:Foster Jonathan P.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:259,688Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5300 Memorial Dr Ste 950 HOUSTON TX 77007-8274 |
Tel: | 1-833-4758247 |
Website: | https://moleculin.com |
IR: | See website |
Key People | ||
Walter V. Klemp Chairman of the Board, President, Chief Executive Officer | Jonathan P. Foster Chief Financial Officer, Executive Vice President | Donald H. Picker Chief Scientific Officer | Paul Waymack Senior Chief Medical Officer |
Business Overview |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG). |
Financial Overview |
For the fiscal year ended 31 December 2023, Moleculin Biotech Inc revenues was not reported. Net loss increased 3% to $29.8M. Higher net loss reflects (Loss) gain from change in fair value of decrease from $1.3M (income) to $1M (expense), Research and development - Balancing val increase of 3% to $18M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$15.22 to -$15.07. |
Employees: | 18 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$29.50M as of Dec 31, 2023 |
Net annual income (TTM): | -$29.77M as of Dec 31, 2023 |
Free cash flow (TTM): | -$24.23M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,227,513 as of Mar 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |